Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 4/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15353768 | 0.84 | ADRA2A (0.41) | BACE1KCNH2TAAR1ADRA2ACYP11B1 | |
| SCHEMBL15216779 | 0.81 | CYP11B1 (0.33) | BACE1KCNH2ALDH1A1KMT2ACYP11B1 | |
| SCHEMBL15216778 | 0.81 | CYP11B1 (0.33) | BACE1KCNH2ALDH1A1KMT2ACYP11B1 | |
| SCHEMBL15216781 | 0.81 | CYP11B1 (0.33) | BACE1KCNH2ALDH1A1KMT2ACYP11B1 | |
| SCHEMBL7922911 | 0.81 | TAAR1 (0.42) | BACE1KCNH2TAAR1ADRA2A | |
| SCHEMBL7923832 | 0.81 | TAAR1 (0.49) | BACE1KCNH2TAAR1ADRA2A | |
| SCHEMBL7928655 | 0.81 | TAAR1 (0.49) | BACE1KCNH2TAAR1ADRA2A | |
| SCHEMBL7928648 | 0.81 | TAAR1 (0.49) | BACE1KCNH2TAAR1ADRA2A | |
| SCHEMBL7917980 | 0.80 | TAAR1 (0.54) | BACE1KCNH2TAAR1ADRA2A | |
| SCHEMBL7916818 | 0.80 | CYP11B1 (0.33) | BACE1KCNH2TAAR1ADRA2ACYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569312-B2 | Biaryl-spiroaminooxzaoline analogues as alpha 2C adrenergic receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2013-10-29 | — | — | US | disclosed |
| US-20130225582-A1 | BIARYL-SPIROAMINOOXZAOLINE ANALOGUES AS ALPHA 2C ADRENERGIC RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. (US) | 2013-08-29 | — | — | US | disclosed |
| US-8476274-B2 | Biaryl spiroaminooxazoline analogues as Alpha2C adrenergic receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2013-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225582-A1 | BIARYL-SPIROAMINOOXZAOLINE ANALOGUES AS ALPHA 2C ADRENERGIC RECEPTOR MODULATORS | ADRA2C, ADRB2, ADRA2A | BACE1 2333/4885KCNH2 884/4885ALDH1A1 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.